Cargando…

Autophagy inhibition: a new therapeutic target in spinal muscular atrophy

Detalles Bibliográficos
Autores principales:	Piras, Antonio, Boido, Marina
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Medknow Publications & Media Pvt Ltd 2018
Materias:	Perspective
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5998633/ https://www.ncbi.nlm.nih.gov/pubmed/29863009 http://dx.doi.org/10.4103/1673-5374.232473

Ejemplares similares

Neuromuscular Junctions as Key Contributors and Therapeutic Targets in Spinal Muscular Atrophy
por: Boido, Marina, et al.
Publicado: (2016)

Inhibition of autophagy delays motoneuron degeneration and extends lifespan in a mouse model of spinal muscular atrophy
por: Piras, Antonio, et al.
Publicado: (2017)

Drug Screening and Drug Repositioning as Promising Therapeutic Approaches for Spinal Muscular Atrophy Treatment
por: Menduti, Giovanna, et al.
Publicado: (2020)

Circulating microRNAs as potential biomarkers and therapeutic targets in spinal muscular atrophy
por: Chen, Tai-Heng
Publicado: (2020)

The contribution of mouse models to understanding the pathogenesis of spinal muscular atrophy
por: Sleigh, James N., et al.
Publicado: (2011)

Increasing Agrin Function Antagonizes Muscle Atrophy and Motor Impairment in Spinal Muscular Atrophy
por: Boido, Marina, et al.
Publicado: (2018)

Experience and Perspectives in the US on the Evolving Treatment Landscape in Spinal Muscular Atrophy
por: Ramos-Platt, Leigh, et al.
Publicado: (2022)

Pharmacological c-Jun NH(2)-Terminal Kinase (JNK) Pathway Inhibition Reduces Severity of Spinal Muscular Atrophy Disease in Mice
por: Schellino, Roberta, et al.
Publicado: (2018)

Organotypic spinal cord cultures: An in vitro 3D model to preliminary screen treatments for spinal muscular atrophy
por: Boido, Marina, et al.
Publicado: (2021)

GEMINs: potential therapeutic targets for spinal muscular atrophy?
por: Borg, Rebecca, et al.
Publicado: (2014)

Neurodevelopmental defects as a primer of neurodegeneration: lessons from spinal muscular atrophy and Huntington’s disease
por: Grice, Stuart J., et al.
Publicado: (2023)

Advances in spinal muscular atrophy therapeutics
por: Parente, Valeria, et al.
Publicado: (2018)

Permissibility of prenatal diagnosis and abortion for fetuses with severe genetic disorder: type 1 spinal muscular atrophy
por: Sasongko, Teguh H., et al.
Publicado: (2010)

Molecular Pathogenesis and New Therapeutic Dimensions for Spinal Muscular Atrophy
por: López-Cortés, Andrés, et al.
Publicado: (2022)

Intrathecal nusinersen administration in adult spinal muscular atrophy patients with complex spinal anatomy
por: Cordts, Isabell, et al.
Publicado: (2020)

What Genetics Has Told Us and How It Can Inform Future Experiments for Spinal Muscular Atrophy, a Perspective
por: Blatnik, Anton J., et al.
Publicado: (2021)

Nusinersen as a Therapeutic Agent for Spinal Muscular Atrophy
por: Li, Qing
Publicado: (2020)

Spinal muscular atrophy
por: D'Amico, Adele, et al.
Publicado: (2011)

Zinc finger protein ZPR1: promising survival motor neuron protein-dependent modifier for the rescue of spinal muscular atrophy
por: Cuartas, Juliana, et al.
Publicado: (2022)

ERK MAPK signaling pathway inhibition as a potential target to prevent autophagy alterations in Spinal Muscular Atrophy motoneurons
por: Sansa, Alba, et al.
Publicado: (2023)

Neuropathology and Therapeutic Intervention in Spinal and Bulbar Muscular Atrophy
por: Banno, Haruhiko, et al.
Publicado: (2009)

Therapeutic strategies for spinal muscular atrophy: SMN and beyond
por: Bowerman, Melissa, et al.
Publicado: (2017)

Innovating spinal muscular atrophy models in the therapeutic era
por: Signoria, Ilaria, et al.
Publicado: (2023)

Agonist of growth hormone-releasing hormone improves the disease features of spinal muscular atrophy mice
por: Boido, Marina, et al.
Publicado: (2023)

Neuronal activity regulates DROSHA via autophagy in spinal muscular atrophy
por: Gonçalves, Inês do Carmo G., et al.
Publicado: (2018)

NADPH oxidase 4 inhibition is a complementary therapeutic strategy for spinal muscular atrophy
por: El Khoury, Mirella, et al.
Publicado: (2023)

Bicalutamide and Trehalose Ameliorate Spinal and Bulbar Muscular Atrophy Pathology in Mice
por: Galbiati, Mariarita, et al.
Publicado: (2023)

OPA1 Dominant Optic Atrophy: Pathogenesis and Therapeutic Targets
por: Wong, David C. S., et al.
Publicado: (2023)

Nusinersen for spinal muscular atrophy
por: Wurster, Claudia D., et al.
Publicado: (2018)

Spinal Muscular Atrophy and Ependymoma
por: Albakr, Aishah, et al.
Publicado: (2017)

Risdiplam for spinal muscular atrophy
Publicado: (2022)

Spinal muscular atrophy: from tissue specificity to therapeutic strategies
por: Iascone, Daniel M., et al.
Publicado: (2015)

Spinal Muscular Atrophy Therapeutics: Where do we Stand?
por: d’Ydewalle, Constantin, et al.
Publicado: (2015)

Spinal Muscular Atrophy Therapeutics in India: Parental Hopes and Despair!
por: Suthar, Renu, et al.
Publicado: (2021)

Spinal muscular atrophy: From approved therapies to future therapeutic targets for personalized medicine
por: Chaytow, Helena, et al.
Publicado: (2021)

Targeting the 5′ untranslated region of SMN2 as a therapeutic strategy for spinal muscular atrophy
por: Winkelsas, Audrey M., et al.
Publicado: (2021)

Spinal muscular atrophy disease: a literature review for therapeutic strategies
por: Stavarachi, M, et al.
Publicado: (2010)

Growth patterns in children with spinal muscular atrophy
por: De Amicis, Ramona, et al.
Publicado: (2021)

Therapy Development for Spinal Muscular Atrophy in SMN Independent Targets
por: Tsai, Li-Kai
Publicado: (2012)

Modeling Spinal Muscular Atrophy in Drosophila
por: Chang, Howard Chia-Hao, et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_nnko6nc3v5snihj8l3t404ii6n